All terms
Request for Designation
Formal mechanism to obtain a binding FDA decision on which Center will regulate a product.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
An RFD is submitted to the Office of Combination Products to determine the classification of a product (drug, device, biologic, or combination) and assign the lead FDA Center based on primary mode of action. What the regulation says
The FDA, under 21 CFR Part 3, outlines the process for submitting a Request for Designation (RFD) to the Office of Combination Products (OCP). This submission helps determine the regulatory classification of a medical product, such as a drug, device, biologic, or combination product, and designates the lead FDA Center for its review based on its primary mode of action. The OCP then issues a designation letter that clarifies the regulatory pathway and applicable requirements.
What this means in practice
Often used early in development for novel combination products to remove ambiguity about the regulatory pathway and applicable cGMP requirements.Examples
- A company developing a drug-eluting stent submits an RFD to confirm it will be regulated as a device with a drug component, with CDRH as the lead center.
- A manufacturer of a diagnostic test that also delivers a therapeutic agent files an RFD to determine if it is considered a combination product and which FDA centers will be involved.
- A startup with a novel biologic delivered via a specialized injector submits an RFD to ensure proper classification and to identify the correct regulatory pathway under CDER or CBER.
Common pitfalls
- •A common pitfall is submitting an RFD too late in the development process, which can lead to costly delays if the product is misclassified.
- •Failing to provide a clear and well-supported primary mode of action in the RFD can result in an unfavorable or delayed designation.
- •Assuming an RFD is only for novel combination products is a mistake, as it can also be beneficial for products with unclear classifications.
- •Not thoroughly understanding the distinctions between drug, device, and biologic classifications can lead to an inaccurate RFD submission.
Frequently asked questions
The primary purpose of an RFD is to obtain a formal FDA determination of a medical product's regulatory classification and the assignment of the lead FDA Center responsible for its premarket review and regulation.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Regulatory
· Same categoryRegulatory
510(k) Premarket Notification(510(k))
FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
Regulatory
510(k) Summary vs 510(k) Statement
Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.
Regulatory
513(g) Request for Information(513(g))
Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.
Regulatory
Abbreviated 510(k)
510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.
Mentioned in recent activity
3 entriesLatest in MedTech
Recent regulatory actions, publications, and trials matched to this term. Updated daily.
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
FDA·1European Commission·1IMDRF·1
- 1
FDA - Medical DevicesVerifiedFDAfda.gov
- 2
European Commission - Medical DevicesVerifiedEuropean Commissionhealth.ec.europa.eu
- 3
IMDRF DocumentsVerifiedIMDRFimdrf.org
Inline markers like [1] jump to the matching reference above.